Effect of sodium-glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, platform trial.
- DOI
- 10.1016/s2213-8587(24)00218-3
- Published
- 2024 Oct
- Container
- The lancet. Diabetes & endocrinology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/s2213-8587-24-00218-3,
title = {Effect of sodium-glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, platform trial.},
author = {Kosiborod MN and Windsor SL and Vardeny O and Berger JS and Reynolds HR and Boumakis S and Althouse AD and Solomon SD and Bhatt AS and Peikert A and Luther JF and Leifer ES and Kindzelski AL and Cushman M and Ng Gong M and Kornblith LZ and Khatri P and Kim KS and Baumann Kreuziger L and Javaheri A and Carpio C and Wahid L and Lopez-Sendon Moreno J and Alonso A and Ho MQ and Lopez-Sendon J and Lopes RD and Curtis JL and Kirwan BA and Geraci MW and Neal MD and Hochman JS and ACTIV-4a Investigators},
year = {2024},
journal = {The lancet. Diabetes \& endocrinology},
doi = {10.1016/s2213-8587(24)00218-3},
url = {https://doi.org/10.1016/s2213-8587(24)00218-3}
}RIS
TY - JOUR TI - Effect of sodium-glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, platform trial. AU - Kosiborod MN AU - Windsor SL AU - Vardeny O AU - Berger JS AU - Reynolds HR AU - Boumakis S AU - Althouse AD AU - Solomon SD AU - Bhatt AS AU - Peikert A AU - Luther JF AU - Leifer ES AU - Kindzelski AL AU - Cushman M AU - Ng Gong M AU - Kornblith LZ AU - Khatri P AU - Kim KS AU - Baumann Kreuziger L AU - Javaheri A AU - Carpio C AU - Wahid L AU - Lopez-Sendon Moreno J AU - Alonso A AU - Ho MQ AU - Lopez-Sendon J AU - Lopes RD AU - Curtis JL AU - Kirwan BA AU - Geraci MW AU - Neal MD AU - Hochman JS AU - ACTIV-4a Investigators PY - 2024 JO - The lancet. Diabetes & endocrinology DO - 10.1016/s2213-8587(24)00218-3 UR - https://doi.org/10.1016/s2213-8587(24)00218-3 ER -
APA
MN, K., SL, W., O, V., JS, B., HR, R., S, B., AD, A., SD, S., AS, B., A, P., JF, L., ES, L., AL, K., M, C., M, N. G., LZ, K., P, K., KS, K., L, B. K., A, J., C, C., L, W., J, L. M., A, A., MQ, H., J, L., RD, L., JL, C., BA, K., MW, G., MD, N., JS, H., & Investigators, A. (2024). Effect of sodium-glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, platform trial.. The lancet. Diabetes & endocrinology. https://doi.org/10.1016/s2213-8587(24)00218-3
Source records
- pubmed · retrieved 2026-09-26T19:48:53.950Z